Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 237

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy

Open access
Sun, Lillian, Clavijo, Paul E., Robbins, Yvette, Patel, Priya, Friedman, Jay, Greene, Sarah, Das, Rita, Silvin, Chris, Van Waes, Carter, Horn, Lucas A., Schlom, Jeffrey, Palena, Claudia, Maeda, Dean, Zebala, John, Allen, Clint T. · 2019 · JCI Insight

Abstract

Recruitment of myeloid-derived suppressor cells (MDSCs) into tumors induces local immunosuppression in carcinomas. Here, we assessed whether SX-682, an orally bioavailable small-molecule inhibitor of CXCR1 and CXCR2, could block tumor MDSC recruitment and enhance T cell activation and antitumor immunity following multiple forms of immunotherapy. CXCR2+ neutrophilic MDSCs (PMN-MDSCs) were the most abundant myeloid cell subset within oral and lung syngeneic carcinomas. PMN-MDSCs demonstrated greater suppression of tumor-infiltrating lymphocyte killing of targets compared with macrophages. SX-682 significantly inhibited trafficking of PMN-MDSCs without altering CXCR2 ligand expression. Trafficking of CXCR1+ macrophages was unaltered, possibly due to coexpression of CSF1R. Reduced PMN-MDSC tumor infiltration correlated with enhanced accumulation of endogenous or adoptively transferred T cells. Accordingly, tumor growth inhibition or the rate of established tumor rejection following programed death-axis (PD-axis) immune checkpoint blockade or adoptive cell transfer of engineered T cells was enhanced in combination with SX-682. Despite CXCR1/2 expression on tumor cells, SX-682 appeared to have little direct antitumor effect on these carcinoma models. These data suggest that tumor-infiltrating CXCR2+ PMN-MDSCs may prevent optimal responses following both PD-axis immune checkpoint blockade and adoptive T cell transfer therapy. Abrogation of PMN-MDSC trafficking with SX-682 enhances T cell-based immunotherapeutic efficacy and may be of benefit to patients with MDSC-infiltrated cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.126853

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 237

Metadata

Authors
Sun, L., Clavijo, P. E., Robbins, Y., Patel, P., Friedman, J., Greene, S., Das, R., Silvin, C., Van Waes, C., Horn, L. A., Schlom, J., Palena, C., Maeda, D., Zebala, J., & Allen, C. T.
Venue
JCI Insight
Published
2019-04-04
Volume
4
Issue
7
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2935366665
Cited by
237
References
11
FWCI
10.33
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. https://app.cochat.ai/papers/10.1172/jci.insight.126853
The paper
Sun, L., Clavijo, P. E., Robbins, Y., Patel, P., Friedman, J., Greene, S., Das, R., Silvin, C., Van Waes, C., Horn, L. A., Schlom, J., Palena, C., Maeda, D., Zebala, J., & Allen, C. T. (2019). Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. https://doi.org/10.1172/jci.insight.126853

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.